Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123849 · ClinicalTrials.gov registry record · Phase 2
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT02123849: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02123849 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02123849, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers. Smokers are at increased risk of developing lung cancer. Acetylsalicylic acid may be useful in preventing lung cancer.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02123849
The ClinicalTrials.gov registry entry for NCT02123849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02123849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02123849 about?
NCT02123849 is a clinical study titled "Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers". This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers. Smokers are at increased risk of developing lung cancer. Acetylsalicylic acid may be useful in preventing lu...
What is the current status of trial NCT02123849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2014-06. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02123849?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Aspirin (DRUG).
Who is sponsoring clinical trial NCT02123849?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.